House Energy & Commerce Committee to hold a hearing The Subcommittee on Health holds a hearing entitled, "21st Century Cures: The Presidentís Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation" with EVP Sara Radcliffe of Biotech Industry Organization and Dr. Garry Neil of Medgenics on May 20 at 10 am. Webcast Link
Medgenics reports Q3 EPS (21c) vs. (33c) last year Gross research and development expenses for the three months ended September 30 decreased to $2.28M from $2.45M for same period in 2013. This decrease was due mainly to a decrease in subcontractor costs. Net R&D expenses for the three months ended September 30 decreased to $1.57M from $2.34M for the same period in 2013. The decrease in net R&D expenses was due to an increase of $0.61M in the participation by the Israeli Office of the Chief Scientist in addition to the decrease in gross R&D expenses. General and administrative expenses for the three months ended September 30 were $2.31M, decreasing from $2.56M for the same period in 2013 primarily due to a decrease in professional fees.